Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9571885 | 0.98 | LMNA (0.62) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6157815 | 0.94 | APP (0.64) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL23440397 | 0.91 | LMNA (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL25297779 | 0.89 | LMNA (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL10609652 | 0.87 | LMNA (0.75) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL339813 | 0.87 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL27367676 | 0.87 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Tetrahydrofuran SCHEMBL28032446 | 0.87 | KMT2A (0.51) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2023885 | 0.84 | LTA4H (0.64) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL7865593 | 0.84 | LTA4H (0.48) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY | 2024-07-18 | — | — | US | claimed |
| CN-118221532-A | Synthesis method of dobutamine hydrochloride | 上海现代哈森（商丘）药业有限公司 | 2024-06-21 | — | — | CN | claimed |
| EP-4344689-A2 | SYNTHESIS OF COELENTERAZINE | International Paper Company (US) | 2024-04-03 | — | — | EP | claimed |
| US-11926624-B2 | Synthesis of coelenterazine synthesis intermediate | INTERNATIONAL PAPER COMPANY (US) | 2024-03-12 | — | — | US | claimed |
| EP-3966214-B1 | SYNTHESIS OF COELENTERAZINE | INT PAPER CO (US) | 2023-12-13 | — | — | EP | claimed |
| EP-2903737-B1 | HIGH-PERFORMANCE ANION EXCHANGE MEMBRANES AND METHODS OF MAKING SAME | EVOQUA WATER TECH LLC (US) | 2022-05-04 | — | — | EP | claimed |
| CN-114080390-A | Synthesis of coelenterazine | 国际纸业公司 | 2022-02-22 | — | — | CN | claimed |
| US-20210332044-A1 | SYNTHESIS OF COELENTERAZINE SYNTHESIS INTERMEDIATE | INTERNATIONAL PAPER COMPANY (US) | 2021-10-28 | — | — | US | claimed |
| US-11078200-B2 | Synthesis of coelenterazine | INTERNATIONAL PAPER COMPANY (US) | 2021-08-03 | — | — | US | claimed |
| US-20210070762-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY (US) | 2021-03-11 | — | — | US | claimed |
| WO-2020226883-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY (US) | 2020-11-12 | — | — | WO | claimed |
| US-20200239471-A1 | SYNTHESIS OF COELENTERAZINE | ALLY BANK, AS COLLATERAL AGENT | 2020-07-30 | — | — | US | claimed |
| US-10626029-B2 | High-performance anion exchange membranes and methods of making same | EVOQUA WATER TECHNOLOGIES LLC (US) | 2020-04-21 | — | — | US | claimed |
| CN-104703697-B | High performance anion exchange membranes and methods of making same | 懿华水处理技术有限责任公司 | 2018-11-23 | — | — | CN | claimed |
| CN-104703697-A | High performance anion exchange membranes and methods of making same | EVOQUA WATER TECHNOLOGIES LLC | 2015-06-10 | — | — | CN | claimed |
| US-4412082-A | Method for preparing 4-hydroxyphenylacetic acid | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1983-10-25 | — | — | US | claimed |
| JP-57149241-A | — | — | None | — | — | JP | disclosed |
| JP-1186884-A | — | — | None | — | — | JP | disclosed |
| US-3935214-A | ANTICOAGULANT | DONAU-PHARMAZIE GESELLSCHAFT M.B.H. (OE) | 1976-01-27 | — | — | US | disclosed |
| US-3932452-A | 1-Arylmethyl-2-imidazolidinones | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | ACHE, UROD, DDT | LMNA 4726/4885CYP1A2 144/4885PTGS1 1910/4885 |
| US-20210070762-A1 | SYNTHESIS OF COELENTERAZINE | ACHE, UROD, DDT | LMNA 4726/4885CYP1A2 144/4885PTGS1 1910/4885 |
| US-11926624-B2 | Synthesis of coelenterazine synthesis intermediate | DCXR, SI, UROD | LMNA 4650/4885CYP1A2 52/4885PTGS1 1253/4885 |
| US-11078200-B2 | Synthesis of coelenterazine | ACHE, UROD, DDT | LMNA 4726/4885CYP1A2 144/4885PTGS1 1910/4885 |
| US-20200239471-A1 | SYNTHESIS OF COELENTERAZINE | ACHE, UROD, DDT | LMNA 4726/4885CYP1A2 144/4885PTGS1 1910/4885 |
| US-20210332044-A1 | SYNTHESIS OF COELENTERAZINE SYNTHESIS INTERMEDIATE | DCXR, SI, UROD | LMNA 4650/4885CYP1A2 52/4885PTGS1 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.